From: Metabolomic approach to profile functional and metabolic changes in heart failure
Group A (N = 9) | Group B (N = 9) | Group C (N = 15) | |
---|---|---|---|
Age (years) | 64.9 ± 8.3 | 66.1 ± 7.9 | 66.7 ± 9.9 |
M/F | 7/2 | 8/2 | 10/5 |
Height (m) | 1.63 ± 0.06 | 1.67 ± 0.51 | 1.67 ± 0.45 |
Weight (kg) | 67.2 ± 12.4 | 74.0 ± 10.6 | 72.9 ±9.6 |
BMI (kg/m2) | 25.2 ± 3.2 | 26.4 ± 3.9 | 26.04 ± 2.7 |
BSA (m2) | 1.74 ± 0.17 | 1.85 ± 0.20 | 1.84 ± 0.26 |
Diabetes | 1 | 1 | 1 |
NYHA class | |||
I | 9 | 8 | 0 |
II | 0 | 1 | 2 |
III | 0 | 0 | 13* |
IV | 0 | 0 | 0 |
Aetiology | |||
Ischaemic | – | 4 | 7 |
Valvular | – | 1 | 1 |
DCM | – | 4 | 6 |
Hypertensive | – | 0 | 1 |
Other | – | 0 | 0 |
Drugs | |||
β-blockers | 9 | 14 | |
ACE-inhibitors | – | 6 | 9 |
ARBs | – | 3 | 6 |
Diuretics | – | 7 | 15 |
Aldosterone antagonists | – | 3 | 5 |
Ca-antagonists | – | 4 | 1 |
Antiarrythmics | – | 1 | 2 |
Acetylsalicylic acid | – | 6 | 10 |
Antiplatelet agents | – | 0 | 1 |
Anticoagulants | – | 1 | 2 |
Statins | – | 7 | 9 |
Other hypolipidemic agents | – | 0 | 3 |
Insulin | – | 1 | 1 |
Oral antidiabetic agents | – | 1 | 1 |
Digoxin | – | 1 | 1 |
Nitroderivates | – | 2 | 0 |
Other antihypertensive drugs | – | 1 | 0 |